Subscribe To
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sha...
November 4, 2023, 5:37 pm
Tyg index helps identify young cad patients and predict their risk of developing target lesion failure
China: A recent study has shown a positive association of the triglyceride-glucose (TyG) index with early-onset coronary artery disease (EOCAD) and in...
October 29, 2023, 7:44 pm
Roche's (rhhby) ms drug reduces brain lesions in phase ii study
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain ...
October 16, 2023, 2:17 pm
Apellis announces preliminary u.s. net revenues of approximately $74 million for syfovre® (pegcetacoplan injection) in the third quarter of 2023
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting i...
October 5, 2023, 11:00 am
Alpha tau announces robust long-term safety and efficacy data from multiple clinical trials of alpha dart
– 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89%...
August 17, 2023, 9:00 pm
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected s...
July 30, 2023, 5:00 pm
Curium receives marketing authorization in the eu for pylclari™, an innovative 18f-psma pet tracer indicated in adults with prostate cancer
PARIS, July 28, 2023 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing aut...
July 28, 2023, 10:12 am
Pure skin laser center brings laser tattoo removal and more to clarkston, mi
CLARKSTON, Mich., June 13, 2023 (GLOBE NEWSWIRE) — Pure Skin Laser Center is an up-and-coming aesthetic practice in Clarkston, Michigan, offering la...
June 13, 2023, 11:28 am
Apellis presents phase 3 functional analyses of syfovre™ (pegcetacoplan injection) for geographic atrophy
Showed visual function and quality-of-life benefits in patients with extrafoveal lesions Slowed the los...
April 23, 2023, 10:05 pm
Belite bio reports full-year 2022 operational highlights and financial results
12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of ...
March 31, 2023, 11:03 pm
Biden had skin cancer removed, doctor says no more treatment needed
WASHINGTON (Reuters) -U.S. President Joe Biden’s February biopsy confirmed that a skin lesion removed...
March 3, 2023, 11:33 pm
Biovaxys technology finalizes us distribution deal with procare health iberia for papilocare gel and oral immunocaps
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) told investors it has now finalized and executed the previously announced US distribution agreement ...
December 19, 2022, 7:54 am
Biovie shares soar 19% premarket after company announces positive results from phase 2 trial of alzheimer's treatment
BioVie Inc. shares BIVI, +22.42% rose 19% in premarket trade Wednesday, after the biotech announced positive results from a Phase 2 trial of its Alzhe...
September 7, 2022, 6:20 am
Todos medical says provista diagnostics lab finishes validation of wound and respiratory pathogen panels; plans to add monkeypox testing
Todos Medical Ltd announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of its PCR-based Wound and Respirator...
August 10, 2022, 11:04 am
Iq-ai signs partnership with bayer to provide its software
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said its medical imaging analysis software, IB Clinic, is now available on the Bayer Calantic platform. Bayer Calan...
July 11, 2022, 3:24 am
Why trevi therapeutics shares trading higher today?
Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a ch...
June 29, 2022, 8:44 am
Apellis' pegcetacoplan showed continuous, meaningful effects at month 18 in geographic atrophy studies
Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegceta...
March 16, 2022, 11:59 am
Apellis shares jump 6% after the company announces new new data for its geographic atrophy drug
Shares of Apellis Pharmaceuticals Inc. APLS, +1.55% gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data d...
March 16, 2022, 8:10 am
Shockwave ivl consistently treats “real world” calcium across multiple peripheral vessel beds
Disrupt PAD III Observational Arm Confirms IVL Safely and Effectively Modifies Superficial and Deep Calcium in Complex Calcified ...
October 6, 2021, 12:15 pm
Shockwave ivl consistently treats “real world” calcium across multiple peripheral vessel beds
Disrupt PAD III Observational Arm Confirms IVL Safely and Effectively Modifies Superficial and Deep Calcium in Complex Calcified ...
October 6, 2021, 12:15 pm